New hope for young hodgkin patients: drug combo may cut radiation need
NCT ID NCT06563245
First seen Mar 21, 2026 · Last updated Apr 29, 2026 · Updated 4 times
Summary
This study tests a new treatment for children, teens, and young adults (ages 2 to 34) with newly diagnosed classical Hodgkin lymphoma. The drug brentuximab vedotin replaces two older drugs in a standard chemo regimen, aiming to shrink tumors faster and reduce the need for radiation. About 96 participants will be enrolled across China, and the study will track how well the cancer responds using PET scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Children's Medical Center
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.